Adding Bevacizumab Improves Overall Survival in NSCLC

Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Related Links:

The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4–ALK-rearranged lung cancer. In the current study, brigatinib was investigated as second-line or later-line treatment in 35 patients who had developed resistance to crizotinib, ceritinib, or alectinib. Most patients (68.6%) received brigatinib as second or third line (range: second to 12th line). In the total cohort, complete and partial responses were obtained for 9.1 and 75.8%, respectively. Overall median progression-free survival was 9.9 months, wh...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
We present the case of a 73-year-old man who presented with an alteration in liver function during treatment with pembrolizumab (anti-programmed death 1 monoclonal antibody) for a stage IV nonsquamous non-small-cell lung cancer, which was initially mistaken for drug-induced irAEs hepatic toxicity.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Publication date: Available online 17 July 2019Source: The Lancet Respiratory MedicineAuthor(s): Juncheng Dai, Jun Lv, Meng Zhu, Yuzhuo Wang, Na Qin, Hongxia Ma, Yong-Qiao He, Ruoxin Zhang, Wen Tan, Jingyi Fan, Tianpei Wang, Hong Zheng, Qi Sun, Lijuan Wang, Mingtao Huang, Zijun Ge, Canqing Yu, Yu Guo, Tong-Min Wang, Jie WangSummaryBackgroundGenetic variation has an important role in the development of non-small-cell lung cancer (NSCLC). However, genetic factors for lung cancer have not been fully identified, especially in Chinese populations, which limits the use of existing polygenic risk scores (PRS) to identify subpopul...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
AbstractSirtuins have emerged as a promising novel class of anti-cancer drug targets. Inhibition of SIRT1 and SIRT2 induces apoptosis in cancer cells and they play multifaceted roles in regulating autophagy. In the present study, we found that salermide, a SIRT1/2-specific inhibitor or small interfering RNAs (siRNAs) to block SIRT1/2 expression could induce autophagy in human NSCLC cells. Moreover, SIRT1/2 inhibition increased the expression levels of ATF4 and DDIT4 and downregulated p-RPS6KB1 and p-EIF4EBP1, two downstream molecules of mTORC1. Moreover, ATF4 or DDIT4 knockdown attenuated salermide-induced autophagy, sugge...
Source: Apoptosis - Category: Molecular Biology Source Type: research
Conclusion :18F-FDG PET/CT metabolic parameters combined with clinicopathological data demonstrated moderate diagnostic efficacy in predicting EGFR mutation status and were associated with prognosis in mutant and wild-type EGFR non-small-cell lung cancer, thus providing a reference for individualized targeted molecular therapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Extracting the DNA from fixation liquid of lung cancer biopsy may be a kind of feasible way to detect EGFR mutation. 
 DOI: 10.3779/j.issn.1009-3419.2019.07.05
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
This article reviews the clinical research progress of immunological checkpoint inhibitors targeting PD-1/PD-L1 in NSCLC. 
 DOI: 10.3779/j.issn.1009-3419.2019.07.06
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
The inflammatory state of tumor microenvironment play an important role in non-small cell lung cancer (NSCLC) drug resistance. As the key signal pathway connecting inflammation and tumor, activated signal transduction and transcriptional activation factor 3 (STAT3) leads togenetic abnormal expression, gene silencing, genomic instability, etc. in tumor cells, and induces therapeutic resistance. STAT3 has thepotential to be a new target for reversal of resistance. In this review, we summarize the progress of STAT3 in acquired drug resistance of NSCLC, explore the possibility of STAT3 as a new target to reverse drug resistanc...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Contributors : Long T Hoang ; Clara Domingo-Sabugo ; Elizabeth S Starren ; Saffron G Willis-Owen ; Deborah J Morris-Rosendahl ; Andrew G Nicholson ; William M Cookson ; Miriam F MoffattSeries Type : Expression profiling by arrayOrganism : Homo sapiensTranscriptomic and genetic profiles of tumours and matched normal tissues could help to identify important factors and potential therapeutic targets that contribute to tumorigenesis. We integrated omics profiles in tumours and matched adjacent normal tissues of patients with LUSC (N = 20) and LUAD (N = 17)
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Alimta | Avastin | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer